pembrolizumab,enfortumab vedotin
merck,astellas,seagen
['ev-103', ' ev ']
#esmo22 ev-103 cohort k shows orr 64.5%, similar to what was published in jco. median dor not yet reached for combination therapy, whereas median dor in ev monotherapy ~13 months. responses seen even in nectin-4 and pd-l1 low tumors. 
Assistant Attending, MSKCC, Genitourinary Oncology Service

Tweets are my own opinions and do not represent the views or opinions of Memorial Sloan Kettering